Corporate governance

As an organisation, we seek to achieve and maintain best practice in corporate governance and the directors acknowledge the importance of the principles of the Quoted Companies Alliance Corporate Governance Code for Small and Mid-Sized Quoted Companies 2013 (QCA Code).

Although the QCA Code is not compulsory for companies listed on the Alternative Investment Market (AIM), the directors apply the principles of the QCA Code to the extent they consider appropriate for a company the size and nature of Vernalis in accordance with the QCA Code.

For a copy of the QCA Code, visit the Quoted Companies Alliance website at www.theqca.com and click on Guides.

Below we have provided pdf copies of the terms of reference for each of our Board Committees together with our Code of Conduct and Ethics policy.

 

Board

Audit Commitee

Remuneration Committee

Nomination & Corporate Governance Committee

Code of Conduct and Ethics

  PDF PDF PDF PDF PDF

Executive Directors

Ian Garland selected     selected  
David Mackney selected        

Non-executive Directors

Peter Fellner

selected (Chair)

    selected (Chair)  
Carol Ferguson selected (SID) selected (Chair) selected selected  
Nigel Sheail selected  selected  selected  
Ian Gilham selected selected selected (Chair) selected  
Lisa Schoenberg selected selected selected selected  

Note: To view PDF files, you will need the Adobe Acrobat Reader. This can be downloaded free of charge from the Adobe website.

Latest News

Unaudited Interim Results for the six months ended 31 December 2016

Vernalis plc (LSE: VER) today announces its unaudited consolidated results for the six month period ended 31 December 2016. 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch